Epigral Ltd
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.
- Market Cap ₹ 6,350 Cr.
- Current Price ₹ 1,472
- High / Low ₹ 2,196 / 1,398
- Stock P/E 15.8
- Book Value ₹ 487
- Dividend Yield 0.41 %
- ROCE 25.1 %
- ROE 22.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,467 | |
| 567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,815 | |
| Operating Profit | 261 | 509 | 689 | 481 | 711 | 651 |
| OPM % | 32% | 33% | 31% | 25% | 28% | 26% |
| 2 | 4 | 8 | 7 | 16 | 18 | |
| Interest | 29 | 44 | 66 | 73 | 53 | 57 |
| Depreciation | 74 | 86 | 109 | 124 | 133 | 151 |
| Profit before tax | 161 | 383 | 522 | 291 | 541 | 462 |
| Tax % | 37% | 34% | 32% | 33% | 34% | |
| 101 | 253 | 353 | 196 | 358 | 402 | |
| EPS in Rs | 24.48 | 60.84 | 85.03 | 47.14 | 82.91 | 93.28 |
| Dividend Payout % | 0% | 0% | 6% | 11% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 42 | 42 | 42 | 42 | 43 | 43 |
| Reserves | 432 | 684 | 1,028 | 1,213 | 1,861 | 2,058 |
| 753 | 993 | 879 | 964 | 593 | 537 | |
| 222 | 405 | 484 | 576 | 655 | 598 | |
| Total Liabilities | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,236 |
| 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | 2,176 | |
| CWIP | 126 | 589 | 158 | 483 | 64 | 309 |
| Investments | 0 | 0 | 21 | 21 | 98 | 45 |
| 221 | 467 | 450 | 524 | 752 | 707 | |
| Total Assets | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,236 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 229 | 284 | 626 | 398 | 441 | |
| -197 | -455 | -437 | -401 | -262 | |
| -32 | 195 | -200 | -8 | -164 | |
| Net Cash Flow | 1 | 24 | -11 | -11 | 15 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 52 | 60 | 28 | 34 | 33 |
| Inventory Days | 51 | 74 | 69 | 90 | 105 |
| Days Payable | 69 | 42 | 36 | 63 | 50 |
| Cash Conversion Cycle | 34 | 92 | 61 | 61 | 88 |
| Working Capital Days | -92 | -26 | -41 | -54 | 26 |
| ROCE % | 29% | 32% | 17% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
28 Nov - One-on-one VC meeting with HSBC Mutual Fund on 1 Dec 2025; no unpublished price-sensitive information.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Nov - Epigral Limited has informed about One-on-One Meeting through V.C. with Investor / Analyst on 1st December, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
21 Nov - Epigral Limited has informed about One-on-One Meeting with Investor / Analyst on 25.11.2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
17 Nov - Epigral Limited has informed about Participation in Conference on 19th November, 2025 and 20th November, 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
13 Nov - Epigral Limited submits Transcript of Conference Call held on Monday, 10th November, 2025 for Q2 FY26 - Results.
Annual reports
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Apr 2024Transcript PPT
-
Apr 2024Transcript PPT REC
-
Apr 2024TranscriptAI SummaryPPT
-
Jan 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Jan 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptAI SummaryPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
Apr 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptAI SummaryPPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptAI SummaryPPT
-
Jun 2022TranscriptAI SummaryPPT
-
Apr 2022Transcript PPT
-
Apr 2022TranscriptAI SummaryPPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Oct 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]